At aTENSION.life, we develop and market innovative and precise diagnostic solutions that enable early and accurate diagnosis as well as targeted - and even personalized - treatment for people with hypertension.
Our proprietary ALDO+ technology platform is based on state-of-the-art mass spectrometry and analyzes the Renin-Angiotensin-Aldosterone System (RAAS) with unparalleled precision from a single blood sample. This allows physicians to accurately identify the causes of treatment-resistant hypertension, without the need for trial-and-error approaches.
The first product from this platform, ALDO+PA, is a CE-IVD-certified blood test for the diagnosis of Primary Aldosteronism (PA), one of the most common yet often overlooked causes of treatment-resistant hypertension. ALDO+PA delivers reliable results without requiring patients to stop their current medication and is available in Austria through our partnership with labors.at.
With our scalable Prep’n’Ship™ model, we make mass spectrometry-based precision diagnostics accessible to any laboratory - regardless of existing infrastructure.
We collaborate with physicians, laboratories, and healthcare institutions to set new standards in hypertension diagnostics and sustainably improve cardiovascular care.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Brehmstraße 14a, Vienna,1110,austria
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.atension.life
- HQ
- Vienna
Atension.life Questions
Atension.Life's website is http://www.atension.life
Atension.Life's LinkedIn profile is https://at.linkedin.com/company/atension-life
Atension.Life has
8 employees.
View email and phone details for 8
employees at Atension.Life.
Atension.Life's industry is
Biotechnology Research
Atension.Life's top competitors are
Covirabio Gmbh,
Tset,
Bit.bio,
Deepopinion,
Vp Venture Partners,
Fynk,
Mavoco,
Froots,
Wlanholding,
Kickscale.
Atension.Life's categories are Biotechnology Research
Atension.Life's founding year is 2024
